A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Lambaréné, Gabon.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2016
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 01 Apr 2015 Status changed from planning to recruiting, as reported in a Public Health Agency of Canada media release.
- 02 Dec 2014 New trial record